Internal Reference Number: FOI_7196
Date Request Received: 22/05/2023 00:00:00
Date Request Replied To: 14/06/2023 00:00:00
This response was sent via: By Email
Request Summary: Usage of high-cost drugs in ophthalmology.
Request Category: Private Individuals
| Question Number 1: For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition: Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab | |
| Answer To Question 1: Jan to Apr 2023: Aflibercept 1350 Bevacizumab 8 Brolucizumab 0 Dexamethasone 10 Faricimab 634 Ranibizumab 11 | |
| Question Number 2: For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy. Aflibercept Bevacizumab Brolucizumab Dexamethasone Faricimab Ranibizumab | |
| Answer To Question 2: Jan to Apr 2023 - New patients Aflibercept 63 Bevacizumab <5 Brolucizumab 0 Dexamethasone 5 Faricimab 35 Ranibizumab 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
